EU PHARMA ASSOCIATIONS WANT ORPHAN DRUG REFORM TO ALLOW EFFECTIVE USE OF SYSTEM
March 1st, 2016
PHARMACOS have called on the European Commission to ensure that a planned review of the European Union (EU) orphan drug regulation allows enough flexibility in the legal definition of such medicines to enable manufacturers to effectively use its fast-track market authorisation. Key comments have come in a public consultation on the proposals from a joint task force on orphan medicinal products and rare diseases between the European Federation of Pharmaceutical Industries and Associations (EFPIA) and EuropaBio (the European Association for BioIndustries). ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.